Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases

N. Guldiken, J. Argemi, B. Gurbuz, SR. Atkinson, M. Oliverius, P. Fila, K. Hamesch, T. Bruns, J. Cabezas, JJ. Lozano, J. Mann, S. Cao, P. Mathurin, VH. Shah, C. Trautwein, MR. Thursz, R. Bataller, P. Strnad

. 2021 ; 19 (1) : 39. [pub] 20210217

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019223

Grantová podpora
MR/R014019/1 Medical Research Council - United Kingdom
MR/R023026/1 Medical Research Council - United Kingdom
U01 AA026978 NIAAA NIH HHS - United States
U01 AA026972 NIAAA NIH HHS - United States

BACKGROUND: Serum transferrin levels represent an independent predictor of mortality in patients with liver failure. Hepatocyte nuclear factor 4 alpha (HNF4α) is a master regulator of hepatocyte functions. The aim of this study was to explore whether serum transferrin reflects HNF4α activity. METHODS: Factors regulating transferrin expression in alcoholic hepatitis (AH) were assessed via transcriptomic/methylomic analysis as well as chromatin immunoprecipitation coupled to DNA sequencing. The findings were corroborated in primary hepatocytes. Serum and liver samples from 40 patients with advanced liver disease of multiple etiologies were also studied. RESULTS: In patients with advanced liver disease, serum transferrin levels correlated with hepatic transferrin expression (r = 0.51, p = 0.01). Immunohistochemical and biochemical tests confirmed reduced HNF4α and transferrin protein levels in individuals with cirrhosis. In AH, hepatic gene-gene correlation analysis in liver transcriptome revealed an enrichment of HNF4α signature in transferrin-correlated transcriptome while transforming growth factor beta 1 (TGFβ1), tumor necrosis factor α (TNFα), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6) negatively associated with transferrin signature. A key regulatory region in transferrin promoter was hypermethylated in patients with AH. In primary hepatocytes, treatment with TGFβ1 or the HNF4α inhibitor BI6015 suppressed transferrin production, while exposure to TNFα, IL-1β, and IL-6 had no effect. The correlation between hepatic HNF4A and transferrin mRNA levels was also seen in advanced liver disease. CONCLUSIONS: Serum transferrin levels constitute a prognostic and mechanistic biomarker. Consequently, they may serve as a surrogate of impaired hepatic HNF4α signaling and liver failure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019223
003      
CZ-PrNML
005      
20210830100806.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12916-021-01917-6 $2 doi
035    __
$a (PubMed)33593348
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Guldiken, Nurdan $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
245    10
$a Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases / $c N. Guldiken, J. Argemi, B. Gurbuz, SR. Atkinson, M. Oliverius, P. Fila, K. Hamesch, T. Bruns, J. Cabezas, JJ. Lozano, J. Mann, S. Cao, P. Mathurin, VH. Shah, C. Trautwein, MR. Thursz, R. Bataller, P. Strnad
520    9_
$a BACKGROUND: Serum transferrin levels represent an independent predictor of mortality in patients with liver failure. Hepatocyte nuclear factor 4 alpha (HNF4α) is a master regulator of hepatocyte functions. The aim of this study was to explore whether serum transferrin reflects HNF4α activity. METHODS: Factors regulating transferrin expression in alcoholic hepatitis (AH) were assessed via transcriptomic/methylomic analysis as well as chromatin immunoprecipitation coupled to DNA sequencing. The findings were corroborated in primary hepatocytes. Serum and liver samples from 40 patients with advanced liver disease of multiple etiologies were also studied. RESULTS: In patients with advanced liver disease, serum transferrin levels correlated with hepatic transferrin expression (r = 0.51, p = 0.01). Immunohistochemical and biochemical tests confirmed reduced HNF4α and transferrin protein levels in individuals with cirrhosis. In AH, hepatic gene-gene correlation analysis in liver transcriptome revealed an enrichment of HNF4α signature in transferrin-correlated transcriptome while transforming growth factor beta 1 (TGFβ1), tumor necrosis factor α (TNFα), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6) negatively associated with transferrin signature. A key regulatory region in transferrin promoter was hypermethylated in patients with AH. In primary hepatocytes, treatment with TGFβ1 or the HNF4α inhibitor BI6015 suppressed transferrin production, while exposure to TNFα, IL-1β, and IL-6 had no effect. The correlation between hepatic HNF4A and transferrin mRNA levels was also seen in advanced liver disease. CONCLUSIONS: Serum transferrin levels constitute a prognostic and mechanistic biomarker. Consequently, they may serve as a surrogate of impaired hepatic HNF4α signaling and liver failure.
650    _2
$a senioři $7 D000368
650    _2
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a hepatocytární jaderné faktory $x metabolismus $7 D051536
650    _2
$a hepatocyty $x metabolismus $x patologie $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a jaterní cirhóza $x metabolismus $7 D008103
650    _2
$a nemoci jater $x metabolismus $x patologie $7 D008107
650    _2
$a nádory jater $x metabolismus $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a messenger RNA $x metabolismus $7 D012333
650    _2
$a transformující růstový faktor beta1 $x metabolismus $7 D053773
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Argemi, Josepmaria $u Pittsburgh Liver Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA $u Liver Unit, Clinica Universidad de Navarra, Hepatology Program, Center for Applied Medical Research, Pamplona, Spain
700    1_
$a Gurbuz, Berivan $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
700    1_
$a Atkinson, Stephen R $u Department of Hepatology, Imperial College London, London, UK
700    1_
$a Oliverius, Martin $u Center of Cardiovascular Surgery and Transplantation Brno, Brno, Czech Republic
700    1_
$a Fila, Petr $u Center of Cardiovascular Surgery and Transplantation Brno, Brno, Czech Republic
700    1_
$a Hamesch, Karim $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
700    1_
$a Bruns, Tony $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
700    1_
$a Cabezas, Joaquín $u Research Institute Valdecilla (Instituto de Investigación Sanitaria Valdecilla), Santander, Spain $u Gastroenterology and Hepatology Unit, University Hospital Marqués de Valdecilla, Santander, Spain
700    1_
$a Lozano, Juan J $u Centro de Investigacion Biomedica en Red, Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
700    1_
$a Mann, Jelena $u Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK
700    1_
$a Cao, Sheng $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Mathurin, Philippe $u Hôpital Claude Huriez, Services des Maladies de l'Appareil Digestif, CHRU Lille, and Unité INSERM 995, Lille, France
700    1_
$a Shah, Vijay H $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Trautwein, Christian $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
700    1_
$a Thursz, Mark R $u Department of Hepatology, Imperial College London, London, UK
700    1_
$a Bataller, Ramon $u Pittsburgh Liver Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
700    1_
$a Strnad, Pavel $u Department of Internal Medicine III, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany. pstrnad@ukaachen.de
773    0_
$w MED00008190 $t BMC medicine $x 1741-7015 $g Roč. 19, č. 1 (2021), s. 39
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33593348 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100806 $b ABA008
999    __
$a ok $b bmc $g 1690120 $s 1139669
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 19 $c 1 $d 39 $e 20210217 $i 1741-7015 $m BMC medicine $n BMC Med $x MED00008190
GRA    __
$a MR/R014019/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a MR/R023026/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a U01 AA026978 $p NIAAA NIH HHS $2 United States
GRA    __
$a U01 AA026972 $p NIAAA NIH HHS $2 United States
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace